- Lymphoma
  - Lymphoma (Hodgkin or Non-Hodgkin)
    - Lymphoma, not otherwise stated
      - **10014:** A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies
      - ***10299:** A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients
    - Diffuse Large B Cell Lymphoma and Hodgkin Lymphoma
      - **10508:** A Phase 1/2 Study of the Combination of Oral DNMT Inhibition and Checkpoint Inhibition in Relapsed DLBCL and HL
  - Non-Hodgkin lymphoma
    - Various Non-Hodgkin lymphomas
      - ***10500:** Phase 1/Expansion study of tazemetostat plus belinostat for the treatment of relapsed or refractory lymphoma
    - Mycosis fungoides (MF) and Sézary syndrome (SS)
      - **10347:** A phase I study with an expansion cohort of duvelisib and nivolumab in mycosis fungoides (MF) and Sézary syndrome (SS)
    - T-cell lymphomas
      - **10335**: A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)
      - **10384:** A Phase 1b/2 Study of Hu5F9-G4 (Magrolimab) in Combination with Mogamulizumab in Relapsed/Refractory Treated T-Cell Lymphoma
      - **10499**: Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas
    - Diffuse large B-cell lymphoma
      - ***10601**: A Phase 1 Study of Mosunetuzumab with Polatuzumab Vedotin and Lenalidomide (M+Pola+Len) in Relapsed/ Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) New
  - Hodgkin lymphoma
    - Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)
      - ***10590:** NORM: Nodular Lymphocyte-Predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase II Trial with Either Rituximab or Mosunetuzumab

NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: November 10, 2022